ManageChatDiscover
418495

The Role of Dapagliflozin in Reducing Anthracycline-Induced Cardiotoxicity in Type 2 Diabetes Mellitus Patients with Breast Cancer

Article

Last updated: 29 Mar 2025

OverviewSimilar Items

Subjects

-

Tags

Clinical Research (Medical)

Abstract

Background: Although anthracyclines are a mainstay of treatment for breast cancer, they can cause serious cardiotoxicity, especially in patients who already have other medical problems including type 2 diabetic mellitus (T2DM).  A sodium-glucose cotransporter-2 (SGLT2) inhibitor called dapagliflozin has demonstrated possible cardioprotective benefits. This study examines whether dapagliflozin can help T2DM patients with breast cancer postpone the development of anthracycline-induced cardiotoxicity. Methods: A total of 112 newly diagnosed breast cancer patients with T2DM were recruited and divided into two groups: the Dapagliflozin Group (n=61), which received dapagliflozin 10 mg in addition to standard antidiabetic therapy, and the Control Group (n=49), which received only standard antidiabetic therapy. Echocardiographic parameters (ejection fraction [EF], global longitudinal strain [GLS]) and biomarkers of cardiotoxicity (troponin I, BNP) were assessed at baseline and follow up at 3 and 6 months. Results: At 3 and 6 months follow up, the Dapagliflozin group showed significantly lower levels of troponin I and BNP, along with better-preserved EF and GLS compared to the control group. The cardioprotective effects of dapagliflozin became more pronounced over time. Receiver Operating Characteristic (ROC) curve analysis demonstrated that dapagliflozin had a strong predictive ability for preventing cardiotoxicity. Conclusion: Dapagliflozin showed significant cardioprotective effects in T2DM patients receiving anthracycline-based chemotherapy, suggesting its potential role in reducing anthracycline-induced cardiotoxicity. Further randomized controlled trials are necessary to confirm the cardioprotective benefits of SGLT2 inhibitors in this patient population.

DOI

10.21608/scumj.2025.418495

Keywords

cardiotoxicity, Dapaglflozine, Anthracyline

Authors

First Name

Mohammed

Last Name

El Merry

MiddleName

Ahmed

Affiliation

Cardiology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

m25merry@gmail.com

City

-

Orcid

0009-0002-4499-1611

First Name

Ahmed

Last Name

Abdellah

MiddleName

Tageldien

Affiliation

Cardiology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

-

City

-

Orcid

-

First Name

Muhammad

Last Name

Soliman

MiddleName

-

Affiliation

Oncology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

-

City

-

Orcid

-

First Name

Mohamed

Last Name

Greash

MiddleName

-

Affiliation

Diabetology Unit - Internal Medicine Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

greash83@yahoo.com

City

-

Orcid

-

First Name

Fathy

Last Name

Nada

MiddleName

A.

Affiliation

Cardiology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Email

fathynada45@hotmail.com

City

-

Orcid

0009-0003-2454-6809

Volume

28

Article Issue

3

Related Issue

53276

Issue Date

2025-03-01

Publish Date

2025-03-01

Page Start

1

Page End

8

Print ISSN

1110-6999

Online ISSN

2090-2581

Article File

SCUMJ_Volume 28_Issue 3_Pages 1-8.pdf

PDF . 336.3kB

Link

https://scumj.journals.ekb.eg/article_418495.html

Detail API

http://journals.ekb.eg?_action=service&article_code=418495

Order

1

Type

Original Article

Type Code

938

Publication Type

Journal

Publication Title

Suez Canal University Medical Journal

Publication Link

https://scumj.journals.ekb.eg/

MainTitle

The Role of Dapagliflozin in Reducing Anthracycline-Induced Cardiotoxicity in Type 2 Diabetes Mellitus Patients with Breast Cancer

Details

Type

Article

Created At

29 Mar 2025